بائل ڈکٹ کینسر
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
کہاں جانا ہے
اس ٹرائل کے لیے انڈیا کے 4 ہاسپٹل مریض لے رہے ہیں۔
رجسٹری کی سمری (ٹیکنیکل)
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
اسپانسر: Jazz Pharmaceuticals
ClinicalTrials.gov پر NCT06282575
رجسٹری پر آخری اپ ڈیٹ 14 Sep 2026 · ہم نے 20 Oct 2026 کو پڑھا